Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 13/20 | 0.86 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6412224 | 0.88 | PKM (0.92) | VCPPKMSMN1; SMN2LMNAHTT | |
| SCHEMBL6403317 | 0.83 | PKM (1.00) | VCPPKMSMN1; SMN2LMNAHTT | |
| SCHEMBL6405241 | 0.80 | L3MBTL1 (0.84) | VCPPKMSMN1; SMN2LMNAHTT | |
| SCHEMBL6405019 | 0.80 | PKM (0.87) | VCPPKMSMN1; SMN2LMNANPSR1 | |
| SCHEMBL6404082 | 0.78 | RXRA (0.74) | VCPPKMSMN1; SMN2LMNAHTT | |
| SCHEMBL6404099 | 0.73 | NPSR1 (0.65) | VCPPKMSMN1; SMN2LMNAHTT | |
| SCHEMBL16409978 | 0.72 | SIRT2 (1.00) | VCPSMN1; SMN2LMNAHTTNPSR1 | |
| SCHEMBL11887417 | 0.70 | KMT2A (0.80) | VCPSMN1; SMN2LMNAHTTNPSR1 | |
| SCHEMBL6403407 | 0.69 | PKM (0.74) | VCPPKMSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL6408696 | 0.68 | ALDH1A1 (0.59) | VCPSMN1; SMN2LMNAHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288347-A1 | Certain triazole-based compounds, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288347-A1 | Certain triazole-based compounds, compositions, and uses thereof | ABCG2, ATP5ME, DNTT | VCP 876/4885PKM 2155/4885SMN1; SMN2 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.